Yoshikazu Murawaki Selected Research

4- (4- cyclohexyl- 2- methyloxazol- 5- yl)- 2- fluorobenzenesulfonamide

5/2010	Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats.
11/2007	Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshikazu Murawaki Research Topics

Disease

37	Neoplasms (Cancer) 01/2018 - 05/2002
35	Hepatocellular Carcinoma (Hepatoma) 03/2016 - 01/2003
19	Fibrosis (Cirrhosis) 01/2020 - 10/2006
19	Liver Cirrhosis (Hepatic Cirrhosis) 05/2014 - 10/2002
14	Liver Diseases (Liver Disease) 01/2017 - 05/2002
7	Carcinoma (Carcinomatosis) 01/2018 - 09/2003
7	Liver Neoplasms (Liver Cancer) 01/2017 - 07/2005
7	Fatty Liver 01/2017 - 08/2004
7	Infections 10/2014 - 08/2006
6	Alcoholic Fatty Liver 01/2020 - 12/2011
6	Carcinogenesis 07/2017 - 09/2003
6	Chronic Hepatitis (Chronic Active Hepatitis) 01/2017 - 10/2003
6	Body Weight (Weight, Body) 03/2016 - 06/2010
6	Chronic Hepatitis C 10/2014 - 07/2005
5	Adenoma (Adenomas) 01/2018 - 09/2003
5	Hepatitis 01/2017 - 03/2006
4	Ascites 05/2014 - 01/2009
3	Non-alcoholic Fatty Liver Disease 01/2020 - 01/2016
3	Hemorrhage 01/2017 - 02/2012
3	Inflammation (Inflammations) 08/2016 - 07/2012
3	Stomach Neoplasms (Stomach Cancer) 08/2015 - 03/2011
3	Chronic Hepatitis B 04/2014 - 01/2012
3	Pleural Effusion (Pleural Effusions) 08/2012 - 09/2004
2	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 02/2008
2	Polyps 01/2018 - 09/2017
2	Necrosis 11/2015 - 09/2004
2	Sclerosis 06/2015 - 02/2007
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2014 - 07/2012
2	Heart Diseases (Heart Disease) 04/2014 - 01/2013
2	Disease Progression 01/2014 - 01/2014
2	Hepatitis B 01/2014 - 01/2009
2	Cholangiocarcinoma 01/2013 - 10/2008
2	Neoplasm Metastasis (Metastasis) 01/2010 - 01/2005
2	Cholestasis 09/2009 - 10/2006
2	Hepatic Encephalopathy 08/2008 - 01/2005
2	Colitis 07/2006 - 04/2005

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 01/2018 - 09/2003
8	Therapeutic UsesIBA 11/2015 - 04/2005
5	MicroRNAs (MicroRNA)IBA 01/2020 - 02/2009
5	Messenger RNA (mRNA)IBA 08/2016 - 05/2005
5	Hydroxyproline (4 Hydroxyproline)IBA 07/2012 - 10/2006
5	Matrix Metalloproteinases (MMPs)IBA 01/2010 - 10/2002
5	CollagenIBA 09/2009 - 10/2002
4	Histidine (L-Histidine)FDA Link 09/2017 - 09/2003
4	Cadherins (E-Cadherin)IBA 07/2017 - 09/2007
4	Tissue Inhibitor of Metalloproteinase-1IBA 08/2016 - 05/2009
4	Transforming Growth Factor beta (TGF-beta)IBA 06/2015 - 01/2003
4	InterferonsIBA 10/2014 - 07/2005
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 02/2007
3	MutL Protein Homolog 1IBA 09/2017 - 09/2003
3	Cytidine DeaminaseIBA 07/2017 - 11/2012
3	Alanine Transaminase (SGPT)IBA 01/2017 - 03/2006
3	Caffeine (No Doz)FDA LinkGeneric 01/2016 - 06/2008
3	perfluorobutane (AI 700)IBA 03/2015 - 02/2012
3	Transaminases (Aminotransferases)IBA 10/2014 - 03/2006
3	Serum AlbuminIBA 05/2014 - 11/2007
3	Tissue Inhibitor of Metalloproteinase-2IBA 08/2013 - 10/2002
3	LipidsIBA 12/2011 - 02/2007
3	Pharmaceutical PreparationsIBA 09/2009 - 05/2007
3	Antiviral Agents (Antivirals)IBA 01/2009 - 08/2006
2	CholesterolIBA 01/2020 - 02/2007
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2017 - 11/2007
2	Phosphates (Orthophosphate)IBA 03/2016 - 05/2010
2	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 01/2016 - 06/2012
2	SonazoidIBA 01/2016 - 03/2015
2	Insulin (Novolin)FDA Link 01/2016 - 11/2007
2	CurcuminIBA 01/2016 - 06/2012
2	EnzymesIBA 11/2015 - 03/2006
2	RNA (Ribonucleic Acid)IBA 10/2014 - 02/2009
2	Ribavirin (Virazole)FDA LinkGeneric 10/2014 - 10/2009
2	Thallium-201IBA 04/2014 - 01/2013
2	HLA-DP Antigens (HLA-DP)IBA 01/2014 - 01/2012
2	HLA-DPA1 antigen (HLA DPA1)IBA 01/2014 - 01/2012
2	HLA-DPB1 antigen (HLA DPB1)IBA 01/2014 - 01/2012
2	CytokinesIBA 01/2014 - 01/2010
2	ferumoxides (Feridex)FDA Link 11/2013 - 07/2012
2	Gemcitabine FDA Link 01/2013 - 10/2008
2	Contrast MediaIBA 10/2012 - 08/2012
2	Small Interfering RNA (siRNA)IBA 09/2012 - 02/2009
2	Angiotensin II Type 1 Receptor BlockersIBA 07/2012 - 10/2006
2	4- (4- cyclohexyl- 2- methyloxazol- 5- yl)- 2- fluorobenzenesulfonamideIBA 05/2010 - 11/2007
2	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 09/2009 - 03/2006
2	candesartanIBA 07/2009 - 10/2006
2	Telomerase (Telomerase Reverse Transcriptase)IBA 02/2009 - 05/2005
2	DNA (Deoxyribonucleic Acid)IBA 01/2009 - 02/2008
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 06/2008 - 12/2006
2	Reactive Oxygen Species (Oxygen Radicals)IBA 02/2008 - 10/2003
2	Glutathione (Reduced Glutathione)IBA 02/2008 - 03/2006
2	Biological ProductsIBA 05/2007 - 11/2005
2	Ethanol (Ethyl Alcohol)IBA 11/2006 - 10/2003
2	Transforming Growth Factor beta1 (TGF beta 1)IBA 10/2006 - 01/2003
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 07/2006 - 04/2005
2	8-Hydroxy-2'-DeoxyguanosineIBA 03/2006 - 10/2003
2	Tissue Inhibitor of MetalloproteinasesIBA 01/2004 - 10/2002
1	Alkaline PhosphataseIBA 01/2020
1	Insulin-Like Growth Factor I (IGF-1)IBA 01/2020

Therapy/Procedure

14	Therapeutics 01/2017 - 04/2005
13	Radiofrequency Ablation 12/2015 - 06/2003
4	Ligation 06/2010 - 10/2006
3	Drug Therapy (Chemotherapy) 05/2015 - 09/2012